Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vorolanib + everolimus
- Development stage
- Phase 3
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vorolanib (CM082) is a multi-target tyrosine kinase inhibitor developed to inhibit angiogenesis and tumor growth by targeting vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs). Everolimus is an mTOR inhibitor that blocks the mammalian target of rapamycin pathway to suppress cell proliferation and angiogenesis. The combination of vorolanib plus everolimus has been investigated for advanced renal cell carcinoma (RCC), particularly in patients who have progressed after standard therapies. Clinical studies indicate that this combination may improve progression-free survival compared to single-agent therapy[2][3][6]. Vorolanib is developed by Betta Pharmaceutical. Everolimus is marketed under several brand names including Afinitor and Zortress.
- Other names
- vorolanibeverolimus
02
Targets
PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)mTOR (Mammalian target of rapamycin kinase)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on vorolanib + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vorolanib + everolimus.